Prabhakar Mithal1, Lauren E Howard2,3, William J Aronson4,5, Martha K Terris6,7, Matthew R Cooperberg8, Christopher J Kane9, Christopher Amling10, Stephen J Freedland3,11. 1. Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. 2. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA. 3. Division of Urology, Veterans Affairs Medical Center, Durham, NC, USA. 4. Urology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 5. Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA. 6. Section of Urology, Veterans Affairs Medical Center, Augusta, GA, USA. 7. Section of Urology, Medical College of Georgia, Augusta, GA, USA. 8. Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. 9. Urology Department, University of California San Diego Health System, San Diego, CA, USA. 10. Division of Urology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA. 11. Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Abstract
OBJECTIVE: To assess the impact of positive surgical margins (PSMs) on long-term outcomes after radical prostatectomy (RP), including metastasis, castrate-resistant prostate cancer (CRPC), and prostate cancer-specific mortality (PCSM). PATIENTS AND METHODS: Retrospective study of 4,051 men in the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort treated by RP from 1988 to 2013. Proportional hazard models were used to estimate hazard ratios (HRs) of PSMs in predicting biochemical recurrence (BCR), CRPC, metastases, and PCSM. To determine if PSMs were more predictive in certain patients, analyses were stratified by pathological Gleason score, stage, and preoperative prostate-specific antigen (PSA) level. RESULTS: The median (interquartile range) follow-up was 6.6 (3.2-10.6) years and 1 127 patients had >10 years of follow-up. During this time, 302 (32%) men had BCR, 112 (3%) developed CRPC, 144 (4%) developed metastases, and 83 (2%) died from prostate cancer. There were 1,600 (40%) men with PSMs. In unadjusted models, PSMs were significantly associated with all adverse outcomes: BCR, CRPC, metastases and PCSM (all P ≤ 0.001). After adjusting for demographic and pathological characteristics, PSMs were associated with increased risk of only BCR (HR 1.98, P < 0.001), and not CRPC, metastases, or PCSM (HR ≤1.29, P > 0.18). Similar results were seen when stratified by pathological Gleason score, stage, or PSA level, and when patients who underwent adjuvant radiotherapy were excluded. CONCLUSIONS: PSMs after RP are not an independent risk factor for CRPC, metastasis, or PCSM overall or within any subset. In the absence of other high-risk features, PSMs alone may not be an indication for adjuvant radiotherapy.
OBJECTIVE: To assess the impact of positive surgical margins (PSMs) on long-term outcomes after radical prostatectomy (RP), including metastasis, castrate-resistant prostate cancer (CRPC), and prostate cancer-specific mortality (PCSM). PATIENTS AND METHODS: Retrospective study of 4,051 men in the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort treated by RP from 1988 to 2013. Proportional hazard models were used to estimate hazard ratios (HRs) of PSMs in predicting biochemical recurrence (BCR), CRPC, metastases, and PCSM. To determine if PSMs were more predictive in certain patients, analyses were stratified by pathological Gleason score, stage, and preoperative prostate-specific antigen (PSA) level. RESULTS: The median (interquartile range) follow-up was 6.6 (3.2-10.6) years and 1 127 patients had >10 years of follow-up. During this time, 302 (32%) men had BCR, 112 (3%) developed CRPC, 144 (4%) developed metastases, and 83 (2%) died from prostate cancer. There were 1,600 (40%) men with PSMs. In unadjusted models, PSMs were significantly associated with all adverse outcomes: BCR, CRPC, metastases and PCSM (all P ≤ 0.001). After adjusting for demographic and pathological characteristics, PSMs were associated with increased risk of only BCR (HR 1.98, P < 0.001), and not CRPC, metastases, or PCSM (HR ≤1.29, P > 0.18). Similar results were seen when stratified by pathological Gleason score, stage, or PSA level, and when patients who underwent adjuvant radiotherapy were excluded. CONCLUSIONS: PSMs after RP are not an independent risk factor for CRPC, metastasis, or PCSM overall or within any subset. In the absence of other high-risk features, PSMs alone may not be an indication for adjuvant radiotherapy.
Authors: Pierre I Karakiewicz; James A Eastham; Markus Graefen; Ilias Cagiannos; Phillip D Stricker; Eric Klein; Thomas Cangiano; Fritz H Schröder; Peter T Scardino; Michael W Kattan Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: Andrew J Stephenson; David P Wood; Michael W Kattan; Eric A Klein; Peter T Scardino; James A Eastham; Brett S Carver Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: G D Grossfeld; J J Chang; J M Broering; D P Miller; J Yu; S C Flanders; J M Henning; D M Stier; P R Carroll Journal: J Urol Date: 2000-04 Impact factor: 7.450
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: JAMA Date: 2006-11-15 Impact factor: 56.272
Authors: Stephen A Boorjian; R Jeffrey Karnes; Paul L Crispen; Rachel E Carlson; Laureano J Rangel; Eric J Bergstralh; Michael L Blute Journal: J Urol Date: 2010-01-21 Impact factor: 7.450
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: J Urol Date: 2009-01-23 Impact factor: 7.450
Authors: H Wadhwa; M K Terris; W J Aronson; C J Kane; C L Amling; M R Cooperberg; S J Freedland; M R Abern Journal: Prostate Cancer Prostatic Dis Date: 2016-10-04 Impact factor: 5.554
Authors: Enric Carbonell; Roger Matheu; Maria Muní; Joan Sureda; Mónica García-Sorroche; María José Ribal; Antonio Alcaraz; Antoni Vilaseca Journal: Biomedicines Date: 2022-08-07
Authors: Mariangela Bellangino; Clare Verrill; Tom Leslie; Richard W Bell; Freddie C Hamdy; Alastair D Lamb Journal: Curr Urol Rep Date: 2017-11-07 Impact factor: 3.092